For the Inventor, By the Inventor

Enter inventor name

Gérard Moinet

USPTO Granted Patents = 26 (Patent Applications = 3)

CIPO Patents = 7 (Patent Applications = 1)

EPO Patents = 11 (Patent Applications = 6)

Average Co-Inventor Count = 3.0

ph-index = 5

Forward Citations = 77(Granted Patents)

Company Filing History:

Merck Patent Gmbh

Merck Patent Gesellschaft MIT Beschrankter Haftung

Albert Rolland S.a.

Merck Patent Gesellschaft MIT

9. 1 out of 100

Merck Patent Gesellschaft MIT Beschraenkter Haftung

10. 1 out of 121

Merck Patent Gesellschaft

Years Active: 1990-2022

Loading Chart...

Loading Chart...

Loading Chart...

26 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11324743 - Treatment for the non alcoholic steatohepatitis and fibrosis (2022-05-10),

2. 9545387 - Composition and kit comprising piperazine derivatives and metformin, and use thereof in the treatment of diabetes (2017-01-17),

3. 9150529 - Piperazine derivatives, methods for preparing same, and uses thereof in the treatment of insulin resistance (2015-10-06),

4. 9150523 - Piperazine derivatives, methods for preparing same, and uses thereof in the treatment of insulin resistance (2015-10-06),

5. 9120805 - Substituted pyrrolo[1,2-A]pyrazin-1-ones and pyrazolo[1,5-A]pyrazin-4-ones as inhibitors of tankyrase and poly(ADP-ribose)polymerase activity (2015-09-01),

6. 8791115 - Combination of triazine derivatives and insulin sensitisers (2014-07-29),

7. 8673955 - Imidazole derivatives as fructose-1,6-bisphosphatase inhibitors and pharmaceutical compositions containing them (2014-03-18),

8. 8362057 - Imidazolecarboxamide derivatives as fructose-1,6-bisphosphatase inhibitors, and pharmaceutical compositions comprising same (2013-01-29),

9. 8329738 - Use of AMPK-activating imidazole derivatives, preparation process therefor and pharmaceutical compositions comprising them (2012-12-11),

10. 8227465 - Combination of triazine derivatives and insulin secretion stimulators (2012-07-24),

11. 8217040 - Use of triazine derivatives for the manufacture of a medicament having a cicatrising or angiogenic effect (2012-07-10),

12. 7897644 - Use of 4-oxobutanoic acid derivatives in the treatment of inflammation (2011-03-01),

13. 7816397 - Phenylcarboxylic acid derivatives and use thereof for the treatment of diabetes (2010-10-19),

14. 7767676 - Dihydro-1,3,5-triazine amine derivatives and their therapeutic uses (2010-08-03),

15. 7727977 - Kynurenine 3-hydroxylase inhibitors for the treatment of diabetes (2010-06-01),

Title: The Innovative Contributions of Gérard Moinet

Introduction

Gérard Moinet, a prominent inventor based in Orsay, France, has made significant strides in the field of pharmaceuticals, holding an impressive 15 patents. His work primarily focuses on treatments for metabolic conditions, showcasing his commitment to advancing medical science and improving patient health.

Latest Patents

Among Gérard Moinet's most recent patents are groundbreaking methods for treating non-alcoholic steatohepatitis (NASH) and related fibrosis. His innovative compounds are designed to prevent or treat these conditions effectively. Additionally, he has developed a composition and kit that combines piperazine derivatives with metformin for treating diabetes. This formulation aims to aid patients dealing with diseases linked to insulin resistance syndrome, demonstrating his dedication to tackling pressing health issues.

Career Highlights

Moinet's career includes esteemed collaborations with notable companies, including Merck Patent GmbH and Poxel S.A.S. His experience in these organizations has allowed him to refine his research and patent strategies, contributing to the development of effective pharmaceutical solutions.

Collaborations

In his journey as an inventor, Gérard Moinet has partnered with esteemed professionals such as Daniel Cravo and Micheline R. Kergoat. These collaborations have fostered a dynamic interchange of ideas and expertise, enhancing the impact of his innovative contributions to the pharmaceutical industry.

Conclusion

Gérard Moinet’s work exemplifies the essence of innovation in healthcare. Through his patents and collaboration with industry leaders, he continues to pave the way for advancements in treatments that have the potential to alter patient outcomes significantly. His legacy as an inventor is not only defined by the number of patents he holds but also by the change he is fostering in the realm of medicine.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com

Loading…